Harbin Pharmaceutical Group Co., Ltd. (SHA:600664)

Revenue by Product

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012	FY 2011	FY 2010	FY 2009	FY 2008	FY 2007	FY 2006	FY 2005
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012	Dec 31, 2011	Dec 31, 2010	Dec 31, 2009	Dec 31, 2008	Dec 31, 2007	Dec 31, 2006	Dec 31, 2005
Wholesale Medical Customers	5.96B
Wholesale Medical Customers Growth	-3.02%
Nutritional Supplements	3.75B
Nutritional Supplements Growth	30.96%
Wholesale Commercial Customers	2.26B
Wholesale Commercial Customers Growth	-9.51%
Retail	1.69B
Retail Growth	5.67%
Anti-virus and Anti-infection	1.00B
Anti-virus and Anti-infection Growth	-1.52%
Cold Medicine	395.32M
Cold Medicine Growth	-26.30%
Cardiovascular	329.83M
Cardiovascular Growth	48.88%
Industrial - Other	316.63M
Anti-tumor	286.31M
Anti-tumor Growth	33.67%
Other	175.69M
Other Growth	84.89%

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012	FY 2011	FY 2010	FY 2009	FY 2008	FY 2007	FY 2006	FY 2005
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012	Dec 31, 2011	Dec 31, 2010	Dec 31, 2009	Dec 31, 2008	Dec 31, 2007	Dec 31, 2006	Dec 31, 2005
China	14.72B
China Growth	2.29%
Overseas	1.46B
Overseas Growth	36.40%